

Drug	Indication	Decision	Notes
Lisdexamfetamine (<i>Elvanse</i>) caps	ADHD - unresponsive to methylphenidate	AMBER	Pro-drug of dexamfetamine with the advantage of once daily dosing. Approved as second line to methylphenidate, as an alternative to atomoxetine. Existing shared care guidelines will be reviewed.
Eplerenone (<i>Inspira</i>) tabs	Heart failure	GREEN	Licence extension - approved as second line to spironolactone
Lixisenatide (<i>Lyxumia</i>)	Type 2 diabetes	GREEN	Lower cost third GLP-1 analogue. Once daily dosing but limited experience and no long-term safety data. Ongoing EMA safety review of existing drugs in this class and gliptins
Racecadotril (<i>Hidrasec</i>)	Diarrhoea	RED-RED	Antihypersecretory agent. Non UK trials demonstrate use with ORS improves recovery vs. ORS alone in children and similar efficacy to loperamide in adults. Limited role in the UK where majority recover with no treatment or ORS.
Nepafenac (<i>Nevanac</i>) 1mg/ml eye drops	Cataract surgery	RED-RED	NSAID eye drop. Lower cost option, ketorolac eye drops (<i>Acular</i>) preferred.
Methylnatrexone (<i>Relistor</i>) s.c. inj.	Opioid induced constipation	AMBER	NICE TA 277 terminated - no evidence submitted by manufacturer. Use on advice of palliative care specialist only (no formal shared care)
Glyceryl trinitrate 0.4% ointment (<i>Rectogesic</i>)	Anal fissures	GREEN	Unlicensed products reviewed by NICE as part of their Evidence Summaries Unlicensed & Off-label Medicines (ESUOM 03 & 07). Diltiazem ointment (£147) is more expensive than diltiazem cream (£93) with no evidence of benefit.
Glyceryl trinitrate 0.2% ointment		GREEN	
Diltiazem 2% cream		GREEN	
Diltiazem 2% ointment		RED-RED	
Colistimethate DP inhalation (<i>Colobreathe</i>)	Treatment of Pseudomonas lung infection in CF	AMBER	Approved by NICE in TA276 as second line to nebulised colomycin & tobramycin, with criteria. Will require shared care guideline or support package from specialist centre.
Tobramycin DP inhalation (<i>TOBI Podhaler</i>)			